Processing

Please wait...

Settings

Settings

1. WO1996005818 - METHODS AND COMPOUNDS ACTIVE AT METABOTROPIC GLUTAMATE RECEPTORS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES

Publication Number WO/1996/005818
Publication Date 29.02.1996
International Application No. PCT/US1995/010745
International Filing Date 21.08.1995
Chapter 2 Demand Filed 12.03.1996
IPC
A61K 31/135 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines, e.g. amantadine
135having aromatic rings, e.g. methadone
A61K 31/335 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 31/35 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
A61K 31/40 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/415 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4151,2-Diazoles
A61K 31/425 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425Thiazoles
CPC
A61K 31/135
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines
135having aromatic rings ; , e.g. ketamine, nortriptyline
A61K 31/335
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 31/35
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
A61K 31/40
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/415
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
4151,2-Diazoles
A61K 31/425
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
425Thiazoles
Applicants
  • NPS PHARMACEUTICALS, INC. [US/US]; Suite 240 420 Chipeta Way Salt Lake City, UT 84108-1256, US
Inventors
  • FULLER, Forrest, H.; US
  • VANWAGENEN, Bradford, C.; US
  • BALANDRIN, Manuel, F.; US
  • DELMAR, Eric, G.; US
  • MOE, Scott, T.; US
  • HUNG, Benjamin, Chein-Pin; US
Agents
  • WARBURG, Richard, J. ; Lyon & Lyon Suite 4700 633 West Fifth Street Los Angeles, CA 90071, US
Priority Data
08/293,53819.08.1994US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS AND COMPOUNDS ACTIVE AT METABOTROPIC GLUTAMATE RECEPTORS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES
(FR) PROCEDES ET COMPOSES ACTIFS AU NIVEAU DES RECEPTEURS DE GLUTAMATE METABOTROPIQUES, DESTINES AU TRAITEMENT D'AFFECTIONS ET DE TROUBLES NEUROLOGIQUES
Abstract
(EN)
The present invention concerns compounds and methods for modulating metabotropic glutamate receptor activity. The compounds are targeted to a binding site on the metabotropic glutamate receptor which appears to be distinct from the glutamate receptor binding site. The preferred use of the compounds and methods of the present invention is to modulate metabotropic glutamate receptor activity and thereby aid in the treatment of neurological diseases or disorders. The compounds can also be used to produce other effects such as an analgesic effect, cognition-enhancement effect, and a muscle-relaxant effect.
(FR)
La présente invention se rapporte à des composés et des procédés de modulation de l'activité des récepteurs de glutamate métabotropiques. Les composés sont ciblés par rapport à un site de liaison sur le récepteur de glutamate métabotropique qui se distingue du site de liaison du récepteur de glutamate. Selon un mode préféré d'utilisation de ces composés et procédés, on module l'activité du récepteur de glutamate métabotropique et on facilite ainsi le traitement des maladies et troubles neurologiques. Les composés peuvent être également utilisés pour produire d'autres effets tels qu'un effet analgésique, un effet améliorant la cognition et un effet de relaxant musculaire.
Also published as
Latest bibliographic data on file with the International Bureau